Association of Genetic Polymorphism of GSTM1 and GSTT1 with the Susceptibility to Antituberculosis Drug-induced Hepatotoxicity in Chinese Population

Source:
By:Gang Xiao

DOI: https://doi.org/10.30564/jams.v1i3.56

Abstract: Objective To investigate the relationship between the polymorphism of glutathione S transferase M1, T1(GSTM1, GSTT1) gene and the susceptibility to antituberculosis drug induced hepatotoxicity (ATDH) in patients with tuberculosis. Methods GSTM1 and GSTT1 gene polymorphisms in patients with or without liver toxicity after antituberculous treatment were analyzed using multiple PCR method. Results In ATDH group and control group, the proportion of GSTM1 gene deletion was 58.0% and 50.7%respectively, and the difference was not statistically signifcant (OR=1.322, 95%CI=0.921~1.878), the frequencies of GSTT1 deletion were 46.3% and 49.3%, respectively, and there was no signifcant difference between them. There was no signifcant difference in frequency of GSTM1 and GSTT1 variation between case group and control group (P> 0.05), and no synergistic effect of those two gene polymorphism were detected in the occurrence of antituberculosis drug-induced hepatotoxicity. Conclusion The polymorphisms of GSTM1 and GSTT1 genes may not be associated with the risk of ATDH.

References:

[1] V. Ramappa, G.P. Aithal, Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management,Journal of clinical and experimental hepatology, 3 (2013)37-49. [2] M. Richardson, J. Kirkham, K. Dwan, D. Sloan, G. Davies, A.Jorgensen, Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol), Systematic reviews, 6 (2017) 142. [3] C. Dye, C.J. Watt, D.M. Bleed, S.M. Hosseini, M.C. Raviglione, Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally, Jama, 293 (2005) 2767-2775. [4] Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity [J]. Pharmacogenomics,2008 9(3):311-321. [5] Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity [J] .Respirology, 2006, 11(6):699-707. [6] Agal S,Baijal R,Pramanik S, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity[J].J Gastroenterol Hepatol, 2005, 20(11):1745-1752. [7] Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review[J]. J Gastroenterol Hepatol, 2008, 23(2):192-202. [8] Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy[J]. Am J Resp ir Crit.Care Med, 2006, 174(8):935-952. [9] Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis[J]. J Gastroenterol Hepatol, 2011, 26(2):312-318. [10] Naisbitt DJ, Williams DP, Pirmohamed M ,et al. Reactive metabolites and their role in drug reactions[J]. Curr Opin Allergy Clin.Immunol, 2001, 1(4):317-325. [11] Strange RC, Jones PW, Fryer AA. Glutathione S-transferase: genetics and role in toxicology [J]. Toxicol lett,2000,112-113:357–363. [12] Roy B1, Chowdhury A, Kundu S, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation[J].Journal of Gastroenterology and Hepatology, 2001, 16(9):1033–1037. [13] Yi-Shin Huang, Wei-Juin Su, Yi-Hsiang Huang, et al. Genetic polymorphisms of manganese superoxide dismutase,NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury[J]. Journal of Hepatology , 2007, 47(1):128–134. [14] Virginia Leiro, Alberto Fern ´andez-Villar, Diana Valverde,et al. Infuence of glutathione S –transferase M1 and T1 homozygous null mutations on the riskofantituberculosis drug-induced hepatotoxicity in a Caucasian population[J]. Liver International, 2008, 28(6):835-839. [15] Sang-Heon Kim , Sang-Hoon Kim , Ho Joo Yoon,et al.GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans[J]. Tuberculosis, 2010, 90 (1): 39–43. [16] Tang SW, Lv XZ, Zhang Y, Wu SS, et al. CYP2E1,GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity:a nested case-control study[J]. J Clin Pharm Ther. 2012 ,37(5):588-593. [17] Rana SV, Sharma SK, Ola RP, et al. N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians[J]. J Clin Pharm Ther, 2014 , 39(1):91-96. [18] Chamorro JG, Castagnino JP, Aidar O, et al. Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity[J]. Pharmacogenet Genomics, 2017 , 27(10):363-371. [19] Peatson WR,Verachek WR,Xu SJ, et al. Identfciation of class mugultathoine S - transferase genes GSTM1-GSTM5 on human chromosome lp13 [J]. Am J Hum Ganet, 1993,53(1):220-233. [20] Chatterjee S, Lyle N, Mandal A,et al. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs[J]. J Clin Pharm Ther.2010,35(4):465-70.